[
  {
    "ts": "2025-10-28T16:24:02+00:00",
    "headline": "H.C. Wainwright Reiterates a Buy Rating on Vertex Pharmaceuticals (VRTX)",
    "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the most profitable biotech stocks to buy. H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on October 21, setting a price target of $478. The analyst based the optimistic rating on the positive potential of the company’s kidney franchise, stating that its […]",
    "url": "https://finance.yahoo.com/news/h-c-wainwright-reiterates-buy-162402516.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "580f1b66-ddbe-3283-b4be-e574e31b0308",
      "content": {
        "id": "580f1b66-ddbe-3283-b4be-e574e31b0308",
        "contentType": "STORY",
        "title": "H.C. Wainwright Reiterates a Buy Rating on Vertex Pharmaceuticals (VRTX)",
        "description": "",
        "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the most profitable biotech stocks to buy. H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on October 21, setting a price target of $478. The analyst based the optimistic rating on the positive potential of the company’s kidney franchise, stating that its […]",
        "pubDate": "2025-10-28T16:24:02Z",
        "displayTime": "2025-10-28T16:24:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/1072f698caaab685c17bd7da04c05995",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Is Vertex Pharmaceuticals Incorporated (VRTX) the Best Stock to Buy According to Jim Simons’ Renaissance Technologies?",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/l0DSaAhjgYrGYMIp84u.Dg--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/1072f698caaab685c17bd7da04c05995.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MOpM93.qarjxsgAhhmtxCQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/1072f698caaab685c17bd7da04c05995.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/h-c-wainwright-reiterates-buy-162402516.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/h-c-wainwright-reiterates-buy-162402516.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-28T16:08:38+00:00",
    "headline": "Vertex Pharmaceuticals Stock Rises 8.9% as Pipeline Progress Renews Valuation Debate",
    "summary": "Thinking about what to do with Vertex Pharmaceuticals stock? You are not alone. The biotech powerhouse has seen its shares oscillate lately, drawing more than a few glances from investors deciding whether to get in, stay in, or head for the exits. The last close landed at $420.17, with the stock posting an 8.9% gain over the past 30 days. This has been a solid rebound after a slower patch that saw shares down 1.4% this week and 10.7% over the past year. Looking further back, the story turns...",
    "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-stock-rises-8-160838859.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "9ae31298-b788-3ee5-84d8-20a56e1230d0",
      "content": {
        "id": "9ae31298-b788-3ee5-84d8-20a56e1230d0",
        "contentType": "STORY",
        "title": "Vertex Pharmaceuticals Stock Rises 8.9% as Pipeline Progress Renews Valuation Debate",
        "description": "",
        "summary": "Thinking about what to do with Vertex Pharmaceuticals stock? You are not alone. The biotech powerhouse has seen its shares oscillate lately, drawing more than a few glances from investors deciding whether to get in, stay in, or head for the exits. The last close landed at $420.17, with the stock posting an 8.9% gain over the past 30 days. This has been a solid rebound after a slower patch that saw shares down 1.4% this week and 10.7% over the past year. Looking further back, the story turns...",
        "pubDate": "2025-10-28T16:08:38Z",
        "displayTime": "2025-10-28T16:08:38Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/be31617c737d47553e0bc442fa8fa6d9",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ihFoSuY9PLXURl2kI_sV.w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/be31617c737d47553e0bc442fa8fa6d9.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bIz6sh0rX4c7ACsVP8z51w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/be31617c737d47553e0bc442fa8fa6d9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-stock-rises-8-160838859.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-stock-rises-8-160838859.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-28T15:52:00+00:00",
    "headline": "Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?",
    "summary": "Strong Trikafta/Kaftrio demand, along with contributions from Alyftrek, Casgevy and Journavx, may have helped VRTX outperform in the third quarter.",
    "url": "https://finance.yahoo.com/news/vertex-gears-report-q3-earnings-155200133.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "cfe07315-8940-303e-8e44-4278e23004cd",
      "content": {
        "id": "cfe07315-8940-303e-8e44-4278e23004cd",
        "contentType": "STORY",
        "title": "Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?",
        "description": "",
        "summary": "Strong Trikafta/Kaftrio demand, along with contributions from Alyftrek, Casgevy and Journavx, may have helped VRTX outperform in the third quarter.",
        "pubDate": "2025-10-28T15:52:00Z",
        "displayTime": "2025-10-28T15:52:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/5c26ab1f8b890434759145296588998c",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/clkf5pUY76l.nElrYS4s6w--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5c26ab1f8b890434759145296588998c.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Fd4LKz3FaED4STL9jWy9kw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5c26ab1f8b890434759145296588998c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-gears-report-q3-earnings-155200133.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-gears-report-q3-earnings-155200133.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-28T14:00:19+00:00",
    "headline": "Will Ultragenyx (RARE) Report Negative Q3 Earnings? What You Should Know",
    "summary": "Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finance.yahoo.com/news/ultragenyx-rare-report-negative-q3-140019209.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "1676b757-6bc1-3b1d-baa3-7eedae738ba5",
      "content": {
        "id": "1676b757-6bc1-3b1d-baa3-7eedae738ba5",
        "contentType": "STORY",
        "title": "Will Ultragenyx (RARE) Report Negative Q3 Earnings? What You Should Know",
        "description": "",
        "summary": "Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
        "pubDate": "2025-10-28T14:00:19Z",
        "displayTime": "2025-10-28T14:00:19Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/c65fb4556b91b6c9dc83e4eff25fede0",
          "originalWidth": 3000,
          "originalHeight": 2351,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/22J0oUBDggIxRsu_SBEo3A--~B/aD0yMzUxO3c9MzAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/zacks.com/c65fb4556b91b6c9dc83e4eff25fede0.cf.webp",
              "width": 3000,
              "height": 2351,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/c871s3MwhyhBJ_fCBFL4cw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/c65fb4556b91b6c9dc83e4eff25fede0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/ultragenyx-rare-report-negative-q3-140019209.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ultragenyx-rare-report-negative-q3-140019209.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "RARE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-28T13:53:00+00:00",
    "headline": "If I Could Only Buy 2 Stocks in the Last Quarter of 2025, I'd Pick These",
    "summary": "These two have been neglected by Wall Street too much.",
    "url": "https://www.fool.com/investing/2025/10/28/if-i-could-only-buy-2-stocks-in-the-last-quarter/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "f24cfcfa-a461-3e60-aa2c-262d5d811291",
      "content": {
        "id": "f24cfcfa-a461-3e60-aa2c-262d5d811291",
        "contentType": "STORY",
        "title": "If I Could Only Buy 2 Stocks in the Last Quarter of 2025, I'd Pick These",
        "description": "",
        "summary": "These two have been neglected by Wall Street too much.",
        "pubDate": "2025-10-28T13:53:00Z",
        "displayTime": "2025-10-28T13:53:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/1851312a66a47277faa0bf3832d403f6",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "Physician talking to patient. ",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KqbIrBXGzumkdZM_Zb.6sA--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/1851312a66a47277faa0bf3832d403f6.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ZCat2li3_9M7Vnt0E1MF.w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/1851312a66a47277faa0bf3832d403f6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/10/28/if-i-could-only-buy-2-stocks-in-the-last-quarter/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/could-only-buy-2-stocks-135300841.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]